Article
Pathology
Julien Dagher, Angelique Brunot, Bertrand Evrard, Solene-Florence Kammerer-Jacquet, Marion Beaumont, Laurence Cornevin, Fanny Derquin, Gregory Verhoest, Karim Bensalah, Alexandra Lespagnol, Frederic Dugay, Marc-Antoine Belaud-Rotureau, Frederic Chalmel, Nathalie Rioux-Leclercq
Summary: Metastatic evolution in clear cell renal cell carcinoma is complex, with tumor heterogeneity resulting from clonal evolution playing a role in metastatic dissemination. Using an integrative multiomics strategy, it was found that all sites were heterogeneous and polyclonal, with each tumor site containing two aggressive subclonal populations.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Review
Medicine, General & Internal
Anna Pliszka, Sebastian Rajda, Agata Wawrzyniak, Jerzy Walocha, Michal Polguj, Grzegorz Wysiadecki, Edward Clarke, Michal Golberg, Michal Zarzecki, Krzysztof Balawender
Summary: This systematic review aimed to summarize current knowledge on testicular metastasis of renal cell carcinoma (RCC). It was found that approximately one-third of RCC cases are recognized in its metastatic stage. Testicular metastasis suggests advanced disease stage, with swelling and enlargement of the affected testis as the main symptoms. Understanding the possibility of such RCC metastases is crucial for making an appropriate diagnosis and implementing timely treatment in the management of neoplastic disease.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Yusuke Yano, Takaya Ohno, Kazumasa Komura, Wataru Fukuokaya, Taizo Uchimoto, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shogo Yamazaki, Satoshi Tokushige, Kazuki Nishimura, Takuya Tsujino, Keita Nakamori, Shutaro Yamamoto, Kosuke Iwatani, Fumihiko Urabe, Keiichiro Mori, Takafumi Yanagisawa, Shunsuke Tsuduki, Kiyoshi Takahara, Teruo Inamoto, Jun Miki, Takahiro Kimura, Yoshio Ohno, Ryoichi Shiroki, Haruhito Azuma
Summary: This study evaluated the predictive value of serum CRP level for metastatic renal cell carcinoma treated with first-line ipilimumab and nivolumab. The results indicated that patients with CRP >1 mg/dL had significantly shorter survival than those with CRP <1 mg/dL, regardless of ccRCC or nccRCC.
Article
Oncology
Kimiharu Takamatsu, Ryuichi Mizuno, Yuto Baba, Yota Yasumizu, Nobuyuki Tanaka, Suguru Shirotake, Toshikazu Takeda, Shinya Morita, Kazuhiro Matsumoto, Takeo Kosaka, Hiroshi Asanuma, Masafumi Oyama, Shuji Mikami, Mototsugu Oya
Summary: The study found that on-treatment CRP control could serve as a predictive factor for the efficacy of nivolumab in refractory mRCC patients, with patients in the CRP control group showing significantly longer PFS.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Urology & Nephrology
Brittney H. Cotta, Margaret F. Meagher, Dattatraya Patil, Kazutaka Saito, Sunil H. Patel, Devin N. Patel, Nathan Miller, Raksha Dutt, Cathrine Keiner, Aaron W. Bradshaw, Fang Wan, Ahmed Eldefrawy, Yosuke Yasuda, Yasuhisa Fujii, Viraj Master, Ithaar H. Derweesh
Summary: The study found that elevated preoperative CRP levels were associated with non-cancer mortality and progressive renal functional decline in patients undergoing surgery for localised RCC. Age, CRP levels, and renal function were identified as independent factors associated with non-cancer mortality risk.
Article
Multidisciplinary Sciences
Yu-Kang Chang, Hueng-Chuen Fan, Chi-Chien Lin, Yuan-Hung Wang, Wan-Ni Tsai, Paik-Seong Lim
Summary: This study evaluated the risk of developing end-stage renal disease (ESRD) in diabetes mellitus (DM) patients with and without atrial fibrillation (AF). The results showed that DM patients with AF had an increased risk of ESRD compared to those without AF, and DM patients with hypertension, chronic kidney disease (CKD), or higher Charlson Comorbidity Index scores also had significantly increased ESRD risks.
Article
Oncology
Margaret F. Meagher, Maria C. Mir, Andrea Minervini, Maximilian Kriegmair, Matthias Heck, Francesco Porpiglia, Siska Van Bruwaene, Estefania Linares, Vital Hevia, Maurizio D'Anna, Alessandro Veccia, Eduard Roussel, Francesco Claps, Carlotta Palumbo, Michele Marchioni, Jonathan Afari, Cesare Saitta, Franklin Liu, Jose Rubio, Riccardo Campi, Andrea Mari, Thomas Amiel, Enrico Checcucci, Mireia Musquera, Georgi Guruli, Nicola Pavan, Maarten Albersen, Alessandro Antonelli, Tobias Klatte, Riccardo Autorino, Rana R. McKay, Ithaar H. Derweesh
Summary: The study aimed to determine the accuracy of a proposed two-tier re-classification of the M domain in the TNM staging of RCC. The analysis of patients from the REMARCC database showed that the M2 classification was an independent risk factor for worsened mortality. Comparisons between M1 and M2 groups demonstrated significant differences in overall survival and cancer-specific survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Kazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, Yumina Muto, Ryuta Sobu, Mizuki Kobayashi, Hajime Sasagawa, Soki Kashima, Ryohei Yamamto, Taketoshi Nara, Hideo Akashi, Ryuji Tabata, Satoshi Sato, Mitsuru Saito, Shintaro Narita, Chikara Ohyama, Tomonori Habuchi
Summary: This study investigated primary resistance to NIVO+IPI as a first-line treatment in patients with metastatic renal cell carcinoma (mRCC). It found that approximately 20% of patients developed primary resistant disease (PRD) with worse survival rates. Lymph node metastasis (LNM) was identified as an independent risk factor for PRD.
Article
Medicine, Research & Experimental
Fabiola Lili Sarmiento-Salinas, Andrea Perez-Gonzalez, Adilene Acosta-Casique, Adrian Ix-Ballote, Alfonso Diaz, Samuel Trevino, Nora Hilda Rosas-Murrieta, Lourdes Millan-Perez-Pena, Paola Maycotte
Summary: Cancer is a major global cause of death, with the role of reactive oxygen species (ROS) in cancer development and progression being extensively studied. However, conflicting evidence exists regarding the specific impact of ROS on cancer, which may vary depending on the type of cancer and stage of tumorigenesis. Recent research has focused on exploring the diverse aspects of ROS interaction with cancer at different stages of cancer progression.
Article
Oncology
Maria Carmen Mir, Laurence Albiges, Axel Bex, Milan Hora, Gianluca Giannarini, Alessandro Volpe, Morgan Roupret
Summary: This case describes a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma who responded to second-line therapy after surgery and systemic treatment. Patients with non-clear cell RCC have poor survival and lack specific systemic therapy, highlighting the need for inclusion in clinical trials testing combinations with immunotherapy.
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Urology & Nephrology
Ekaterina Laukhtina, Benjamin Pradere, David D'Andrea, Giuseppe Rosiello, Stefano Luzzago, Angela Pecoraro, Carlotta Palumbo, Sophie Knipper, Pierre Karakiewicz, Vitaly Margulis, Fahad Quhal, Reza Sari Motlagh, Hadi Mostafaei, Keiichiro Mori, Victor M. Schuettfort, Dmitry Enikeev, Shahrokh F. Shariat
Summary: In metastatic renal cell carcinoma patients, a preoperative high SII value (>710) is independently associated with unfavorable clinical outcomes, especially in those with intermediate risk mRCC and increased BMI.
MINERVA UROLOGY AND NEPHROLOGY
(2022)
Article
Urology & Nephrology
Rodrigo Rodrigues Pessoa, Reza Nabavizadeh, Fernando Quevedo, Daniel D. Joyce, Christine M. Lohse, Vidit Sharma, Brian A. Costello, Stephen A. Boorjian, R. Houston Thompson, Bradley C. Leibovich, John C. Cheville
Summary: This study compared different models using clinical, primary tumor, and metastatic features to predict cancer-specific survival for patients with surgically resected metastatic clear cell renal cell carcinoma. The findings showed that scoring algorithms calculated using histopathological features of the metastasis can be used to predict cancer-specific survival, which is particularly important when primary tumor histopathology is not readily available.
JOURNAL OF UROLOGY
(2023)
Article
Oncology
Ahmad Y. Y. Abuhelwa, Joaquim Bellmunt, Ganessan Kichenadasse, Ross A. A. McKinnon, Andrew Rowland, Michael J. J. Sorich, Ashley M. M. Hopkins
Summary: C-reactive protein (CRP) is a powerful prognostic marker for predicting survival in patients with metastatic renal cell carcinoma (mRCC) treated with immunotherapy, with superior predictive ability compared to the International Metastatic RCC Database Consortium (IMDC) model.
FRONTIERS IN ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Koji Iinuma, Risa Tomioka-Inagawa, Koji Kameyama, Tomoki Taniguchi, Kei Kawada, Takashi Ishida, Shingo Nagai, Torai Enomoto, Shota Ueda, Makoto Kawase, Shinichi Takeuchi, Kota Kawase, Daiki Kato, Manabu Takai, Keita Nakane, Takuya Koie
Summary: A multicenter retrospective study evaluated the efficacy and safety of cabozantinib in patients with advanced or metastatic renal cell carcinoma. The study found that cabozantinib is a useful treatment option for mRCC patients and may benefit from earlier use. Additionally, high CRP levels may be a poor prognostic factor in patients treated with cabozantinib, requiring careful follow-up.
Article
Endocrinology & Metabolism
Andrew H. Nguyen, Michael P. O'Leary, James P. De Andrade, Philip H. G. Ituarte, Jonathan Kessler, Daneng Li, Gagandeep Singh, Sue Chang
Summary: Renal neuroendocrine neoplasms are rare and their natural history is poorly understood. The study found that patients with earlier stage and favorable histologies had increased survival rates.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Oncology
Kazuki Okubo, Makoto Isono, Kosuke Miyai, Takako Asano, Akinori Sato
Article
Multidisciplinary Sciences
Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato
Summary: Combining MK-8776 with gemcitabine inhibits viability and colony formation of bladder cancer cells, induces apoptosis, and suppresses tumor growth in vivo. The combination treatment elevates gamma H2A.X and suppresses Rad51 expression, suggesting CHK1 inhibition combined with gemcitabine as a potential therapeutic strategy for bladder cancer.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Kazuki Okubo, Makoto Isono, Takako Asano, Nina Ressing, Wolfgang A. Schulz, Finn K. Hansen, Akinori Sato
Summary: The study found that UPS was activated in cisplatin-resistant bladder cancer cells, and UPS-targeting drugs were more effective in inducing apoptosis and inhibiting growth in cisplatin-resistant cells. Furthermore, these drugs could induce endoplasmic reticulum stress at lower concentrations in cisplatin-resistant bladder cancer cells.
ANTICANCER RESEARCH
(2021)
Article
Oncology
Kazuki Okubo, Kosuke Miyai, Kimi Kato, Takako Asano, Akinori Sato
Summary: The combination of simvastatin and romidepsin induces histone acetylation cooperatively, leading to apoptosis of bladder cancer cells. The activation of AMPK by the combination also results in ER stress, promoting reactive oxygen species production. Additionally, there is a positive feedback loop between ER stress induction and PPAR gamma expression in the combination therapy.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Oncology
Kazuki Okubo, Nina Ressing, Wolfgang A. Schulz, Finn K. Hansen, Takako Asano, Akinori Sato
Summary: Ritonavir enhances the ability of RTS-V5 to induce ER stress in bladder cancer cells by increasing the expression of AMP-activated protein kinase and causing histone and tubulin hyperacetylation.
ANTICANCER RESEARCH
(2021)
Meeting Abstract
Oncology
Takako Asano, Akinori Sato
Meeting Abstract
Oncology
Takako Asano, Kazuki Okubo, Akinori Sato
Meeting Abstract
Oncology
Makoto Isono, Akinori Sato, Kazuki Okubo, Takako Asano, Toshihiko Torigoe
Meeting Abstract
Oncology
Takako Asano, Kazuki Okubo, Akinori Sato
Article
Urology & Nephrology
Kazuki Okubo, Fumiko Hamabe, Kosuke Miyai, Makoto Isono, Hiroshi Shinmoto, Akinori Sato
UROLOGY CASE REPORTS
(2020)
Article
Oncology
Kenji Kuroda, Shinsuke Tasaki, Akinori Sato, Junichi Asakuma, Akio Horiguchi, Keiichi Ito
MOLECULAR AND CLINICAL ONCOLOGY
(2020)
Meeting Abstract
Urology & Nephrology
Takako Asano, Kazuki Okubo, Akinori Sato
JOURNAL OF UROLOGY
(2020)
Meeting Abstract
Urology & Nephrology
Akinori Sato, Takako Asano, Makoto Isono, Kazuki Okubo
JOURNAL OF UROLOGY
(2019)
Meeting Abstract
Urology & Nephrology
Akinori Sato, Takako Asano, Makoto Isono, Kazuki Okubo
JOURNAL OF UROLOGY
(2019)
Meeting Abstract
Urology & Nephrology
Kazuki Okubo, Makoto Isono, Takako Asano, Akinori Sato
JOURNAL OF UROLOGY
(2019)